Completed PHASE2 INTERVENTIONAL 1-arm NCT00193063

Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer

Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer

Sponsor: Eli Lilly and Company

Conditions Breast Cancer

Interventions Gemcitabine Trastuzumab

Updated 5 times since 2017 Last updated: Feb 10, 2014 Started: Jul 31, 2001 Primary completion: May 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
Genentech, Inc.
SCRI Development Innovations, LLC

Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.